{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irradiated+Blood+Transfusions", "query": { "intervention": "Irradiated Blood Transfusions" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 39, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irradiated+Blood+Transfusions&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T18:32:28.066Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04540380", "title": "Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Failure" ], "interventions": [ { "name": "Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab", "type": "DRUG" }, { "name": "Combined bone marrow and kidney transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2021-09-01", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-09-10T18:32:28.066Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04540380" }, { "nct_id": "NCT03910452", "title": "Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Chronic Granulomatous Disease" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Allogeneic peripheral blood stem cell", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "4 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2019-10-28", "completion_date": "2034-06-15", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-10T18:32:28.066Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03910452" }, { "nct_id": "NCT01035229", "title": "Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Everolimus Placebo", "type": "DRUG" }, { "name": "Best Supportive Care (BSC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 546, "start_date": "2010-04", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2016-09-22", "last_synced_at": "2026-09-10T18:32:28.066Z", "location_count": 19, "location_summary": "Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01035229" }, { "nct_id": "NCT02007863", "title": "Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia", "Myelodysplasia", "Acute Lymphocytic Leukemia", "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "Umbilical Cord Blood Transfusion", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 2, "start_date": "2008-08", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2015-12-28", "last_synced_at": "2026-09-10T18:32:28.066Z", "location_count": 2, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02007863" }, { "nct_id": "NCT06078696", "title": "Siplizumab for Sickle Cell Disease Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anemia, Sickle Cell" ], "interventions": [ { "name": "Siplizumab", "type": "DRUG" }, { "name": "Exchange Transfusion", "type": "PROCEDURE" }, { "name": "Total Body Irradiation", "type": "PROCEDURE" }, { "name": "Stem Cell Infusion", "type": "PROCEDURE" }, { "name": "Cyclophosphamide 50mg", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Sirolimus Oral Tablet", "type": "DRUG" }, { "name": "Rituximab or Biosimilar", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 1, "start_date": "2023-09-28", "completion_date": "2025-12-11", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-09-10T18:32:28.066Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06078696" }, { "nct_id": "NCT06872333", "title": "Allo HSCT for High Risk Hemoglobinopathies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Failure", "Sickle Cell Disease", "Hemoglobinopathies" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Plerixafor (mozobil)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 62, "start_date": "2024-11-19", "completion_date": "2032-06-01", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-10T18:32:28.066Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06872333" }, { "nct_id": "NCT03587272", "title": "Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Alemtuzumab, low dose total body irradiation, Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Robert Nickel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 100, "start_date": "2018-04-17", "completion_date": "2030-11", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-09-10T18:32:28.066Z", "location_count": 5, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03587272" }, { "nct_id": "NCT02179359", "title": "Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sickle Cell Disease", "Transfusion Dependent Alpha- or Beta- Thalassemia", "Diamond Blackfan Anemia", "Paroxysmal Nocturnal Hemoglobinuria", "Glanzmann Thrombasthenia", "Severe Congenital Neutropenia", "Shwachman-Diamond Syndrome", "Non-Malignant Hematologic Disorders" ], "interventions": [ { "name": "Reduced Toxicity Ablative Regimen", "type": "DRUG" }, { "name": "Reduced Intensity Preparative Regimen", "type": "DRUG" }, { "name": "Myeloablative Preparative Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 38, "start_date": "2014-09-02", "completion_date": "2024-11-21", "has_results": false, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-09-10T18:32:28.066Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02179359" }, { "nct_id": "NCT00932152", "title": "Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Postmenopausal Women" ], "interventions": [ { "name": "fulvestrant (Faslodex)", "type": "DRUG" }, { "name": "anastrozole (Arimidex)", "type": "DRUG" }, { "name": "Bevacizumab (Avastin)", "type": "DRUG" }, { "name": "Best supportive care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2010-09", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2017-10-19", "last_synced_at": "2026-09-10T18:32:28.066Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00932152" }, { "nct_id": "NCT01773395", "title": "GVAX vs. Placebo for MDS/AML After Allo HSCT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "GVAX", "type": "BIOLOGICAL" }, { "name": "Placebo Vaccine", "type": "BIOLOGICAL" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2013-01-08", "completion_date": "2021-11-24", "has_results": true, "last_update_posted_date": "2022-07-18", "last_synced_at": "2026-09-10T18:32:28.066Z", "location_count": 4, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01773395" } ] }